Uric acid and neurological disease: a narrative review

Hyperuricemia often accompanies hypertension, diabetes, dyslipidemia, metabolic syndrome, and chronic renal disease; it is also closely related to cardiovascular disease. Moreover, several epidemiological studies have linked hyperuricemia and ischemic stroke. However, uric acid may also have neuroprotective effects because of its antioxidant properties. An association between low uric acid levels and neurodegenerative diseases has been suggested, which may be attributed to diminished neuroprotective effects as a result of reduced uric acid. This review will focus on the relationship between uric acid and various neurological diseases including stroke, neuroimmune diseases, and neurodegenerative diseases. When considering both the risk and pathogenesis of neurological diseases, it is important to consider the conflicting dual nature of uric acid as both a vascular risk factor and a neuroprotective factor. This dual nature of uric acid is important because it may help to elucidate the biological role of uric acid in various neurological diseases and provide new insights into the etiology and treatment of these diseases.

[1]  Hojin Choi,et al.  Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study , 2022, Neurological Sciences.

[2]  H. Jinnah,et al.  Uric Acid in Parkinson′s Disease: What Is the Connection? , 2022, Movement disorders : official journal of the Movement Disorder Society.

[3]  E. Mazzon,et al.  Inosine in Neurodegenerative Diseases: From the Bench to the Bedside , 2022, Molecules.

[4]  S. M. Kim,et al.  Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone , 2022, Redox report : communications in free radical research.

[5]  K. Misawa,et al.  Hypouricemia and Urate Transporters , 2022, Biomedicines.

[6]  Min Zhang,et al.  Plasma Uric Acid Helps Predict Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis , 2021, Frontiers in Neurology.

[7]  D. Mozaffarian,et al.  Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. , 2021, JAMA.

[8]  J. Teng,et al.  Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder , 2021, Journal of Neurology.

[9]  R. Yin,et al.  Association between uric acid and the prognosis of acute ischemic stroke: A systematic review and meta-analysis. , 2021, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[10]  P. Shaw,et al.  Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts , 2021, Neurobiology of Aging.

[11]  Qi-Jie Zhang,et al.  Serum Uric Acid Levels Predict Mortality Risk in Male Amyotrophic Lateral Sclerosis Patients , 2021, Frontiers in Neurology.

[12]  A. Rae-Grant,et al.  Diagnosis and Treatment of Multiple Sclerosis: A Review. , 2021, JAMA.

[13]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. , 2021, Circulation.

[14]  A. Tuttolomondo,et al.  Neuroinflammatory Mechanisms in Ischemic Stroke: Focus on Cardioembolic Stroke, Background, and Therapeutic Approaches , 2020, International journal of molecular sciences.

[15]  J. Jankovic,et al.  Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  B. Song,et al.  Serum Uric Acid Level and Multiple Sclerosis: A Mendelian Randomization Study , 2020, Frontiers in Genetics.

[17]  A. Pisani,et al.  Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features , 2020, Neurobiology of Aging.

[18]  M. Kanbay,et al.  The causality between the serum uric acid level and stroke , 2020, Hypertension Research.

[19]  K. Yamagishi,et al.  Serum uric acid and risk of stroke and its types: the Circulatory Risk in Communities Study (CIRCS) , 2020, Hypertension Research.

[20]  G. Sobue,et al.  Prognosis of amyotrophic lateral sclerosis patients undergoing tracheostomy invasive ventilation therapy in Japan , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[21]  S. Larsson with at a Mendelian randomization study. , 2020 .

[22]  N. Limdi,et al.  Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. , 2019, Hypertension.

[23]  G. Feuchtner,et al.  Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. , 2019, JAMA cardiology.

[24]  J. Goudreau,et al.  Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial , 2019, Neurology.

[25]  Sebastian Heinzel,et al.  Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[26]  D. Burn,et al.  Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson’s Disease , 2019, Journal of Parkinson's disease.

[27]  I. Hisatome,et al.  Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy , 2019, European heart journal.

[28]  S. Ito,et al.  Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  Albert A. Taylor,et al.  Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis , 2018, Annals of clinical and translational neurology.

[30]  D. Solomon,et al.  Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. , 2018, Journal of the American College of Cardiology.

[31]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[32]  A. Soumaré,et al.  Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study , 2017, Annals of the rheumatic diseases.

[33]  永井拓,et al.  うつを予防する生活習慣に関する前向きコホート研究:Circulatory Risk in Communities Study(CIRCS) , 2018 .

[34]  A. Ascherio,et al.  Targeting urate to reduce oxidative stress in Parkinson disease , 2017, Experimental Neurology.

[35]  Jin Xue,et al.  Low uric acid is a risk factor in mild cognitive impairment , 2017, Neuropsychiatric disease and treatment.

[36]  Miao Liu,et al.  Relationship between serum uric acid level and mild cognitive impairment in Chinese community elderly , 2017, BMC Neurology.

[37]  F. Guerrero‐Romero,et al.  Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis , 2017, Neurological Sciences.

[38]  Tan Xu,et al.  Sex‐Specific Relationship Between Serum Uric Acid and Risk of Stroke: A Dose‐Response Meta‐Analysis of Prospective Studies , 2017, Journal of the American Heart Association.

[39]  Y. Long,et al.  Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders , 2016, Brain and behavior.

[40]  J. Singh,et al.  Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data , 2016, Annals of the rheumatic diseases.

[41]  L. Marshall Parkinson disease , 2017, Nature Reviews Disease Primers.

[42]  A. Rodrigues,et al.  Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor , 2017, Molecular Neurobiology.

[43]  I. Kubota,et al.  Associations between serum uric acid levels and the incidence of nonfatal stroke: a nationwide community-based cohort study , 2017, Clinical and Experimental Nephrology.

[44]  M. Nagai,et al.  Correction:Serum Uric Acid and Mortality Form Cardiovascular Disease:EPOCH-JAPAN Study , 2016, Journal of atherosclerosis and thrombosis.

[45]  J. Singh,et al.  Allopurinol and the risk of stroke in older adults receiving medicare , 2016, BMC Neurology.

[46]  Jun Wang,et al.  Low serum uric acid levels in patients with multiple sclerosis and neuromyelitis optica: An updated meta-analysis. , 2016, Multiple sclerosis and related disorders.

[47]  A. Rodrigues,et al.  Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor , 2016, Molecular Neurobiology.

[48]  J. Hallas,et al.  Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. , 2016, The American journal of medicine.

[49]  A. Ascherio,et al.  Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[50]  A. Dominiczak,et al.  Allopurinol and Cardiovascular Outcomes in Adults With Hypertension , 2016, Hypertension.

[51]  J. Hewitt,et al.  Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis , 2016, AGE.

[52]  M. Hernán,et al.  Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study , 2015, Annals of the rheumatic diseases.

[53]  C. Chai,et al.  Increased risk of osteoporosis in patients with erectile dysfunction , 2016, Medicine.

[54]  Yangang Wang,et al.  Inverse Association Between Serum Uric Acid Levels and Alzheimer’s Disease Risk , 2016, Molecular Neurobiology.

[55]  Richard J. Johnson Why focus on uric acid? , 2015, Current medical research and opinion.

[56]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[57]  M. Arias Gómez,et al.  Associated Inosine to interferon: results of a clinical trial in multiple sclerosis , 2015, Acta neurologica Scandinavica.

[58]  V. Morra,et al.  Uric acid: a potential biomarker of multiple sclerosis and of its disability , 2015, Clinical chemistry and laboratory medicine.

[59]  C. Russo,et al.  Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study , 2015, Journal of Neurology.

[60]  M. T. Pellecchia,et al.  Uric acid relates to dopamine transporter availability in Parkinson's disease , 2015, Acta neurologica Scandinavica.

[61]  M. T. Pellecchia,et al.  Presence and progression of non‐motor symptoms in relation to uric acid in de novo Parkinson's disease , 2015, European journal of neurology.

[62]  Yun-Jiu Cheng,et al.  Risk of Thromboembolic Events in Atrial Fibrillation With Chronic Kidney Disease , 2015, Stroke.

[63]  Cheng-Li Lin,et al.  A population-based cohort study. , 2015 .

[64]  M. Biddle,et al.  A report from the American Heart Association Council on Cardiovascular and Stroke Nursing. , 2015, The Journal of cardiovascular nursing.

[65]  M. Roudier,et al.  Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study , 2014, BMJ Open.

[66]  Min Li,et al.  Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. , 2014, Atherosclerosis.

[67]  E. Sharifipour,et al.  Allopurinol as a Preventive Contrivance after Acute Ischemic Stroke in Patients with a High Level of Serum Uric Acid: A Randomized, Controlled Trial , 2013, Medical Principles and Practice.

[68]  L. Cui,et al.  Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica , 2013, Journal of Clinical Neuroscience.

[69]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[70]  A. Vincent,et al.  Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO , 2012, Acta neurologica Scandinavica.

[71]  A. Michotte,et al.  Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial , 2010, Multiple sclerosis.

[72]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[73]  Hyon K. Choi,et al.  Hyperuricemia and risk of stroke: a systematic review and meta-analysis. , 2009, Arthritis and rheumatism.

[74]  T. Whitmarsh The treatment of multiple sclerosis with inosine. , 2009, Journal of Alternative and Complementary Medicine.

[75]  R. Castro,et al.  Serum homocysteine: interplay with other circulating and genetic factors in association to Alzheimer's type dementia. , 2009, Clinical biochemistry.

[76]  S. Karumanchi,et al.  Reactions of Peroxynitrite with Uric Acid: Formation of Reactive Intermediates, Alkylated Products and Triuret, and In Vivo Production of Triuret Under Conditions of Oxidative Stress , 2009, Nucleosides, nucleotides & nucleic acids.

[77]  A. Hofman,et al.  Serum uric acid and cognitive function and dementia. , 2008, Brain : a journal of neurology.

[78]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[79]  M. Weisskopf,et al.  Plasma urate and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[80]  T. Nakagawa,et al.  Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. , 2007, American journal of physiology. Cell physiology.

[81]  G. Toncev Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. , 2006, Vojnosanitetski pregled.

[82]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[83]  K. Leung,et al.  Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[84]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[85]  G. Aldini,et al.  Biomarkers of antioxidant capacity in the hydrophilic and lipophilic compartments of human plasma. , 2004, Archives of biochemistry and biophysics.

[86]  Y. Moriwaki,et al.  Effect of inosine on the plasma concentration of uridine and purine bases. , 2002, Metabolism: clinical and experimental.

[87]  H. Koprowski,et al.  Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease , 2001, Multiple sclerosis.

[88]  T. Panetta,et al.  Identification of uric acid and xanthine oxidase in atherosclerotic plaque. , 2001, The American journal of cardiology.

[89]  J. Marinković,et al.  Uric acid levels in sera from patients with multiple sclerosis , 2001, Journal of Neurology.

[90]  F Santeusanio,et al.  Relation Between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension: The PIUMA Study , 2000, Hypertension.

[91]  D. Inzitari,et al.  Parkinson’s disease and parkinsonism in a longitudinal study , 2000, Neurology.

[92]  Robert C. Wolpert,et al.  A Review of the , 1985 .